Oncoinvent ASA
Clinical-stage biotech developing radiopharmaceutical therapies for peritoneal cancers.
OCIN | Euronext Growth
Overview
Corporate Details
- ISIN(s):
- NO0010779341 (+1 more)
- LEI:
- 54930076H5GUZRMSNR39
- Country:
- Norway
- Address:
- Gullhaugveien 7, 0484 Oslo
- Website:
- https://www.oncoinvent.com/
- Sector:
- Manufacturing
Description
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies for cancer. The company's core focus is on direct alpha therapy, a technology platform designed to deliver potent, short-range radiation directly to cancerous tumors. Its lead product candidate, Radspherin®, is composed of inorganic microparticles that carry the alpha-emitting radionuclide Radium-224. This formulation is engineered for regional retention and slow degradation, enabling a high radiation dose to be administered within the peritoneal cavity while minimizing systemic exposure. Oncoinvent's clinical programs are primarily investigating the use of Radspherin® for treating metastatic cancers in the peritoneal cavity, including ovarian and colorectal cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-08 07:00 |
Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Tre…
|
English | 6.0 KB | ||
| 2025-09-17 08:56 |
Oncoinvent ASA: Updated information regarding the contemplated Rights Issue and…
|
English | 89.4 KB | ||
| 2025-09-17 08:56 |
Oncoinvent ASA: Updated information regarding the contemplated Rights Issue and…
|
English | 3.2 KB | ||
| 2025-09-17 08:55 |
Oncoinvent ASA: Updated Key Information related to the contemplated Rights Issu…
|
English | 93.4 KB | ||
| 2025-09-17 08:55 |
Oncoinvent ASA: Updated Key Information related to the contemplated Rights Issue
|
English | 9.6 KB | ||
| 2025-08-27 07:00 |
Oncoinvent ASA half-yearly report: Strong focus on financial discipline and adv…
|
English | 135.5 KB | ||
| 2025-08-27 07:00 |
Oncoinvent ASA half-yearly report: Strong focus on financial discipline and adv…
|
English | 1.2 MB | ||
| 2025-08-27 07:00 |
Oncoinvent ASA half-yearly report: Strong focus on financial discipline and adv…
|
English | 647.1 KB | ||
| 2025-08-27 07:00 |
Oncoinvent ASA half-yearly report: Strong focus on financial discipline and adv…
|
English | 4.5 KB | ||
| 2025-08-22 12:22 |
Oncoinvent ASA invites to a webcast presentation of 1H 2025 on Wednesday 27 Aug…
|
English | 4.2 KB | ||
| 2025-08-04 13:53 |
Oncoinvent shareholders approve the merger plan with BerGenBio - Attachment: On…
|
Norwegian | 111.8 KB | ||
| 2025-08-04 13:53 |
Oncoinvent shareholders approve the merger plan with BerGenBio
|
English | 4.4 KB | ||
| 2025-07-03 15:45 |
Oncoinvent ASA: Notice of Extraordinary General Meeting - Attachment: Oncoinven…
|
Norwegian | 190.2 KB | ||
| 2025-07-03 15:45 |
Oncoinvent ASA: Notice of Extraordinary General Meeting
|
English | 3.6 KB | ||
| 2025-06-30 22:11 |
Announcement of fully underwritten rights issue - Attachment: Attachment_overvi…
|
English | 101.2 KB |
Automate Your Workflow. Get a real-time feed of all Oncoinvent ASA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oncoinvent ASA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oncoinvent ASA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
